Comparison of the efficacy of budesonide by nebulizer, metered dose inhaler and dry powder inhaler in chronic stable bronchial asthma

Dilshad Ali Rizvi, Afroz Abidi, Abhishek Agarwal, Ali Ahmad


Background: The study has been performed to evaluate the efficacy of budesonide delivery by different form of devices like nebulizer, metered dose inhaler and dry powder inhaler to adult patients of chronic stable bronchial asthma. The changes in pulmonary function test parameters have been consider for evaluation.

Methods: This prospective study was undertaken to assess the relative efficiency of budesonide administered from devices like nebulizer, metered dose inhaler and dry powder inhaler in adult patients of chronic stable bronchial asthma. Fifty subjects where administered budesonide (1mg) via nebulizer, budesonide (400 microgram) by metered dose inhaler and dry powder inhaler consecutively each week for four weeks under direct supervision. To analyze the effect of budesonide delivered through different devices pulmonary function test was carried out on the subject before and one hour after administration of the drug on each visit.

Results: No significant difference in Peak expiratory flow rate (P=0.77), forced expiratory volume in one second (P=0.851), forced vital capacity (P=0.178) and forced expiratory volume in one second and forced vital capacity ratio (P=0.298) was seen after giving budesonide by different devices.

Conclusions: Budesonide delivered by different devices (nebulizer, metered dose inhaler, and dry powder inhaler) have similar effect on lung function in patients of chronic stable bronchial asthma. In the daily clinical practice, the correct choice of an inhaler device should be related with the patient's characteristics. They may be used interchangeably depending on availability, cost and compliance of the patients.


Asthma, Budesonide, Comparative study, Inhaled corticosteroid

Full Text:



Morris MJ. Asthma Treatment and Management. Available at: Updated: Jun 16, 2016

Harold K, Mazza J. Practical guide for allergy and immunology in Canada. Allergy, Asthma and clinical Immunology. 2011;7(1):S2(suppl-II).

Dane E, Funda C, Esra KU, Eser GY, Mehmet K, Ercument E, et al. Clinical effectiveness of nebulised budesonide in the treatment of acute asthma attacks. Tuberkuloz ve Torak Dergisti. 2006;54(2):128-36.

American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis. 1987;136:225-43.

Calverley P, Pauwels R, Lofdahl CG, Svensson K, Higenbottam T, Carlsson IG, et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J. 2005;26:406-13.

Standardization of spirometry, 1994 update. American Thoracic Society. Am J Resspir Crit Care Med. 1995;152(3):1107-36.

Barnes PJ. Asthma, In, Harrison’s principle of Internal Medicine (Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo) Diseases of Respiratory System Asthma 17th Edition, McGraw Hill, New Delhi, 2008;1596.

GINA Asthma Management and Prevention, Globalinitiative for Asthma, Global strategy for asthma management and prevention; 2008:64.

Census of India: Provisional Population Total. Registrar and Census Commissioner for India, New Delhi; 2001.

Edinger D, Coskun F, Kunt UE, Giirdal YE, Karadag M, Ege E, et al. Clinical effectiveness of nebulized budesonide in the treatment of acute asthma attacks. Turberk Toraks. 2006;54(2):128-36.

Mahler DA. Peak Inspiratory Flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017 July;14(7):1103-7.

Bisgaard H, Nikander K, Munch E. Comparative study of budesonide as a nebulized suspension vs pressurized metered dose inhaler in adult asthamatics. Respiratory Medicine. 1998;92:44-9.

Engel T, Heinig JH, Malling HJ, Scharling B, Nikander K, Madsen F. Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy. 1989;44:220-5.

Kerwin EM, Pearlman DS, De Guia T, Carlsson LG, Gillen M, Uryniak T, et al. Evaluation of efficacy and safety of budesonide delivered via two dry powder inhalers. Curr Med Res Opin. 2008;24(5):1497-510.

Morice AH, Hochmuth L, Ekelund J, Thoren A, Puterman AS. Comparable long term safety and efficacy of a novel budesonide/formoterol pressurized metered dose inhaler versusbudesonide/formoterol Turbuhaler in adolescents and adults with asthma. Pulm Pharmacol Ther. 2008;21(1):32-9.

Volovitz B. inhaled budesonide in the management of acute worsening and exacerbations of asthma: a review of the evidence. Respir Med. 2007 Apr;101(4):685-95.

Cazzola M, Ora J, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P. Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD. Pulmonary pharmacology & therapeutics. 2016 Aug 1;39:48-53.

Cazzola M, Rogliani P. Controversies in COPD. Chapter 15-Inhaled medication: which device for which patient? ERS Monogr. 2015;69:213-23.

Fromer L, Goodwin E, Walsh J. Customizing inhaled therapy to meet the needs of COPD patients, Postgrad. Med. 2010;122:83-93.